Belgium
· Delayed Price · Currency is EUR Celyad Oncology Statistics
Total Valuation
Celyad Oncology has a market cap or net worth of EUR 19.89 million. The enterprise value is 16.59 million.
| Market Cap | 19.89M |
| Enterprise Value | 16.59M |
Important Dates
The last earnings date was Friday, April 4, 2025.
| Earnings Date | Apr 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Celyad Oncology has 41.43 million shares outstanding. The number of shares has increased by 61.73% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 41.43M |
| Shares Change (YoY) | +61.73% |
| Shares Change (QoQ) | +0.83% |
| Owned by Insiders (%) | 0.53% |
| Owned by Institutions (%) | 0.05% |
| Float | 14.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 106.91 |
| PB Ratio | 38.92 |
| P/TBV Ratio | 40.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.85 |
| EV / Sales | 89.20 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.29, with a Debt / Equity ratio of 1.77.
| Current Ratio | 2.29 |
| Quick Ratio | 1.79 |
| Debt / Equity | 1.77 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -49.33 |
Financial Efficiency
Return on equity (ROE) is -170.92% and return on invested capital (ROIC) is -83.59%.
| Return on Equity (ROE) | -170.92% |
| Return on Assets (ROA) | -28.00% |
| Return on Invested Capital (ROIC) | -83.59% |
| Return on Capital Employed (ROCE) | -82.89% |
| Revenue Per Employee | 10,333 |
| Profits Per Employee | -323,556 |
| Employee Count | 19 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +50.63% in the last 52 weeks. The beta is 1.24, so Celyad Oncology's price volatility has been higher than the market average.
| Beta (5Y) | 1.24 |
| 52-Week Price Change | +50.63% |
| 50-Day Moving Average | 0.53 |
| 200-Day Moving Average | 0.45 |
| Relative Strength Index (RSI) | 45.88 |
| Average Volume (20 Days) | 39,381 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Celyad Oncology had revenue of EUR 186,000 and -5.82 million in losses. Loss per share was -0.14.
| Revenue | 186,000 |
| Gross Profit | 174,000 |
| Operating Income | -5.87M |
| Pretax Income | -5.82M |
| Net Income | -5.82M |
| EBITDA | -5.69M |
| EBIT | -5.87M |
| Loss Per Share | -0.14 |
Balance Sheet
The company has 4.20 million in cash and 905,000 in debt, giving a net cash position of 3.30 million or 0.08 per share.
| Cash & Cash Equivalents | 4.20M |
| Total Debt | 905,000 |
| Net Cash | 3.30M |
| Net Cash Per Share | 0.08 |
| Equity (Book Value) | 511,000 |
| Book Value Per Share | 0.01 |
| Working Capital | 3.67M |
Cash Flow
| Operating Cash Flow | -5.68M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 93.55% |
| Operating Margin | -3,155.91% |
| Pretax Margin | -3,131.18% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Celyad Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -61.73% |
| Shareholder Yield | -61.73% |
| Earnings Yield | -29.29% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Celyad Oncology has an Altman Z-Score of -51.88. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -51.88 |
| Piotroski F-Score | n/a |